Skip to content

Research at St Andrews

MRSA decolonization of cotton rat nares by a combination treatment comprising lysostaphin and the antimicrobial peptide ranalexin

Research output: Contribution to journalArticle

DOI

Author(s)

Andrew Desbois, Abdul Sattar, Shirley Graham, Peter Warne, Peter John Coote

School/Research organisations

Abstract

Objective: To evaluate the in vivo effectiveness of a combination treatment containing ranalexin (a natural antimicrobial peptide)and lysostaphin (an antistaphylococcal endopeptidase) for reducing nasal burden of methicillin resistant Staphylococcus aureus (MRSA).
Methods: The community-acquired MRSA strain S. aureus NRS384 (USA300-0114) was used in the present study because it is commonly isolated from human nares and it established consistent and reproducible colonization of cotton rat nares. This model was used to evaluate the efficacy of ranalexin/lysostaphin gels (0.1%–1% w/v; administered intranasally once or once per day for 3 consecutive days) for reducing nasal MRSA burden. Control animals were administered vehicle gel only (0.5% hydroxypropyl methylcellulose) or 2% mupirocin, which is used clinically for nasal decolonization of MRSA. Nasal MRSA burden was assessed at 192 h post-inoculation, which was at least 72 h after the final treatment had been administered. An additional study assessed the efficacy of 0.1% ranalexin/lysostaphin against a mupirocin-resistant MRSA strain (MUP20), which had been selected by serial passage of S. aureus NRS384 through subinhibitory concentrations of mupirocin.
Results: Gels containing 0.1% ranalexin/lysostaphin consistently reduced median nasal burden of MRSA to an extent similar to or greater extent than 2% mupirocin. Treatment with 0.1% ranalexin/lysostaphin was also effective against the MUP20 strain. There was evidence for only minimal irritancy in cotton rat nares administered three doses of 0.1% ranalexin/lysostaphin, suggesting that this agent is suitable for short-course therapy such as is employed currently for nasal decolonization with mupirocin.
Conclusion: Ranalexin/lysostaphin could serve as an alternative to mupirocin for nasal decolonization of MRSA.
Close

Details

Original languageEnglish
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
DOIs
StatePublished - 2013

    Research areas

  • antibacterials, combination, infection control, isoleucyl-tRNA synthetase, ileS,mupirocin, methicillin-resistant Staphylococcus aureus, nasal carriage

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

Related by journal

  1. Linezolid pharmacokinetics in MDR-TB: a systematic review, meta-analysis and Monte Carlo simulation

    Millard, J., Pertinez, H., Bonnett, L., Model, E. M., Dartois, V., Johnson, J. L., Caws, M., Tiberi, S., Bolhuis, M., Alffenaar, J-W. C., Davies, G. & Sloan, D. J. 23 Mar 2018 In : Journal of Antimicrobial Chemotherapy. 73, 7, p. 1755-1762 8 p.

    Research output: Contribution to journalArticle

  2. Has primary care antimicrobial use really been increasing? Comparison of changes in different prescribing measures for a complete geographic population 1995–2014

    Neilly, M. D. J., Guthrie, B., Hernandez Santiago, V., Vadiveloo, T., Donnan, P. T. & Marwick, C. A. 1 Oct 2017 In : Journal of Antimicrobial Chemotherapy. 72, 10, p. 2921-2930 10 p.

    Research output: Contribution to journalArticle

  3. Improved power for TB phase IIa trials using a model-based pharmacokinetic-pharmacodynamic approach compared with commonly used analysis methods

    Svensson, R. J., Gillespie, S. H. & Simonsson, U. S. H. 1 Aug 2017 In : Journal of Antimicrobial Chemotherapy. 72, 8, p. 2311-2319 9 p.

    Research output: Contribution to journalArticle

  4. ST3268: a geographically widespread primate MRSA clone

    Hsu, L-Y., Holden, M. T. G., Koh, T. H., Pettigrew, K. A., Cao, D., Hon, P. Y., Sergio, D. M., Pena, E. & Ogden, B. E. 1 Aug 2017 In : Journal of Antimicrobial Chemotherapy. 72, 8, p. 2401-2403 2 p.

    Research output: Contribution to journalLetter

  5. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

    Heinrich, N., Dawson, R., du Bois, J., Narunsky, K., Horwith, G., Phipps, A. J., Nacy, C. A., Aarnoutse, R. E., Boeree, M. J., Gillespie, S. H., Venter, A., Henne, S., Rachow, A., Phillips, P. P. J., Hoelscher, M., Diacon, A. H. & Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA) 27 Jan 2015 In : Journal of Antimicrobial Chemotherapy.

    Research output: Contribution to journalArticle

ID: 54611044